Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Nirsevimab, a monoclonal antibody to the RSV fusion protein being developed by AstraZeneca and Sanofi, has an extended half-life, which may allow one dose to confer protection throughout a season.

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

Amid an ongoing shortage of nirsevimab, an RSV immunization for young children, the US Centers for Disease Control and Prevention has announced that more than 77,000 additional doses will be ...

Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season.

Nirsevimab reduced respiratory syncytial virus lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent 1 Results published in New England Journal of Medicine ...

In a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis (95% CI 73.4-89.2) in infants younger than 12 months of age, Naim ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...